论文部分内容阅读
目的探讨联合检测肿瘤组织中核苷酸切除修复交叉互补基因1(ERCC1)和生存素蛋白的表达指导非小细胞肺癌(NSCLC)个体化治疗的价值。方法确诊为NSCLC患者151例,随机进入个体化治疗(A组,101例)和标准治疗(B组,50例)两组。A组依据活检组织标本中ERCC1及生存素蛋白表达情况选择个体化方案化疗:两种蛋白表达均为阴性的患者采用含铂一线化疗方案;其他患者则选用非铂化疗方案。B组均选择含铂一线化疗方案。比较两组患者化疗有效率和总生存期。结果 A组化疗有效率高于B组(49.5%vs.32.0%)(P<0.05);A组中位生存时间比B组长(13.81个月vs.11.50个月)(P<0.05)。结论联合检测肿瘤组织中ERCC1和生存素蛋白指导NSCLC患者个体化治疗可以提高化疗效果,延长生存时间。
Objective To investigate the value of combined detection of nucleotide excision repair cross-complementary gene 1 (ERCC1) and survivin protein expression in the individualized treatment of non-small cell lung cancer (NSCLC). Methods One hundred and fifteen patients diagnosed as NSCLC were randomly divided into two groups: individualized treatment (group A, n = 101) and standard treatment (group B, n = 50). Group A was selected according to biopsy specimens of ERCC1 and survivin protein expression of individualized chemotherapy: two protein-negative patients with platinum first-line chemotherapy; other patients were selected non-platinum chemotherapy. B group were selected platinum first-line chemotherapy. The two groups of patients were compared for chemotherapy efficacy and overall survival. Results The effective rate of chemotherapy in group A was higher than that in group B (49.5% vs.32.0%, P <0.05). The median survival time in group A was longer than that in group B (13.81 months vs.11.50 months) (P <0.05). Conclusion Combined detection of ERCC1 and survivin in tumor tissue can guide the individualized treatment of patients with NSCLC to improve the chemotherapy effect and prolong the survival time.